{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:14:53Z","timestamp":1793150093394,"version":"4.5.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/pat.0b013e328360b61d","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T15:27:58Z","timestamp":1366126078000},"page":"346-356","source":"Crossref","is-referenced-by-count":126,"title":["Clinicopathological relevance of BRAF mutations in human cancer"],"prefix":"10.1016","volume":"45","author":[{"given":"Sahar","family":"Pakneshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salajegheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Anthony Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"King-Yin Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/PAT.0b013e328360b61d_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF-MEK-ERK pathway in cancer therapy","volume":"283","author":"Montagut","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(09)02001-6","article-title":"Ras signaling and therapies","volume":"102","author":"Young","year":"2009","journal-title":"Adv Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02699050500284218","article-title":"The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions","volume":"24","author":"Yoon","year":"2006","journal-title":"Growth Factors"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0020","first-page":"25","article-title":"Raf proteins and cancer: B-Raf is identified as a mutational target","volume":"1653","author":"Mercer","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0030","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/0008-5472.CAN-08-3563","article-title":"Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase\/mitogen- activated protein kinase pathway suppression","volume":"69","author":"Hoeflich","year":"2009","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma","volume":"126","author":"Goel","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0040","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0045","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0055","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopatho- logic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAT.0b013e3283532565","article-title":"Incidence of BRAF p. Val600Glu and p. Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region","volume":"44","author":"Amanuel","year":"2012","journal-title":"Pathology"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.1127515","article-title":"MC1R germline variants confer risk for BRAF-mutant melanoma","volume":"313","author":"Landi","year":"2006","journal-title":"Science"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0070","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1755-148X.2010.00778.x","article-title":"Genetic and morphologic features for melanoma classification","volume":"23","author":"Broekaert","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0075","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pmed.0050120","article-title":"Improving melanoma classification by integrating genetic and morphologic features","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0080","doi-asserted-by":"crossref","first-page":"e25806","DOI":"10.1371\/journal.pone.0025806","article-title":"BRAF mutations in advanced cancers: clinical characteristics and outcomes","volume":"6","author":"El-Osta","year":"2011","journal-title":"PloS One"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0085","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0090","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1385\/EP:16:4:323","article-title":"Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants","volume":"16","author":"Lam","year":"2005","journal-title":"Endocr Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0100","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/modpathol.2010.167","article-title":"Molecular analysis of thyroid tumors","volume":"24","author":"Nikiforov","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0105","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0110","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1158\/1078-0432.CCR-03-0273","article-title":"Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.humpath.2009.09.023","article-title":"Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant","volume":"42","author":"Smith","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0120","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1210\/jc.2004-0172","article-title":"Low frequency ofBRAFT1796A mutations in childhood thyroid carcinomas","volume":"89","author":"Kumagai","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/thy.2005.15.320","article-title":"BRAF mutations are uncommon in papillary thyroid cancer of young patients","volume":"15","author":"Penko","year":"2005","journal-title":"Thyroid"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0130","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2559.2011.04149.x","article-title":"Papillary thyroid carcinomas with and without BRAF? V600E mutations are morphologically distinct","volume":"60","author":"Finkelstein","year":"2012","journal-title":"Histopathology"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0135","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1210\/jc.2003-030305","article-title":"Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers","volume":"88","author":"Namba","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0140","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3349\/ymj.2004.45.5.818","article-title":"Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population","volume":"45","author":"Kim","year":"2004","journal-title":"Yonsei Med J"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1677\/erc.1.01119","article-title":"The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I- targeting to the membrane","volume":"13","author":"Riesco-Eizaguirre","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0150","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1530\/EJE-10-0290","article-title":"BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F] fluoro-2- deoxy-d-glucose uptake ability","volume":"163","author":"Barollo","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0155","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.26500","article-title":"The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer","volume":"118","author":"Kim","year":"2011","journal-title":"Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/pgmj.2007.064881","article-title":"Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists","volume":"84","author":"Salajegheh","year":"2008","journal-title":"Postgrad Med J"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/01.pas.0000135519.34847.f6","article-title":"Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma","volume":"28","author":"Lloyd","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/modpathol.2012.152","article-title":"BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation","volume":"26","author":"Virk","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0175","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/SLA.0b013e31824e8d70","article-title":"Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients","volume":"255","author":"Cahadas-Garre","year":"2012","journal-title":"Ann Surg"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0180","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1210\/jc.2003-032221","article-title":"Analysis of BRAF point mutation and RET\/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma","volume":"89","author":"Salvatore","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.mce.2009.10.012","article-title":"Prognostic utility of BRAF mutation in papillary thyroid cancer","volume":"321","author":"Xing","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0190","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/PAS.0b013e31802f5404","article-title":"BRAF in papillary thyroid carcinoma of ovary (struma ovarii)","volume":"31","author":"Schmidt","year":"2007","journal-title":"Am J SurgPathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1066896906299131","article-title":"BRAF T1799A mutation occurring in a case of malignant struma ovarii","volume":"15","author":"Flavin","year":"2007","journal-title":"Int J Surg Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0200","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/thy.2009.0458","article-title":"Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer","volume":"20","author":"Wolff","year":"2010","journal-title":"Thyroid"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1148\/rg.313105066","article-title":"Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment","volume":"31","author":"Lalwani","year":"2011","journal-title":"Radiographics"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0210","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0215","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ygyno.2006.05.029","article-title":"KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants","volume":"103","author":"Mayr","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0230","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-04-2067","article-title":"Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors","volume":"64","author":"Ho","year":"2004","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2010.01.006","article-title":"Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary","volume":"117","author":"May","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0240","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0245","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0250","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yexmp.2008.03.008","article-title":"Genetic and epigenetic changes in colon cancer","volume":"85","author":"Samowitz","year":"2008","journal-title":"Exp Mol Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0255","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.275.5302.967","article-title":"Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype","volume":"275","author":"Rampino","year":"1997","journal-title":"Science"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0260","doi-asserted-by":"crossref","first-page":"578","DOI":"10.5858\/2010-0613-RAIR.1","article-title":"Molecular diagnostics of colorectal cancer","volume":"135","author":"Bedeir","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3380001","article-title":"Recognition of DNA alterations by the mismatch repair system","volume":"338","author":"Marra","year":"1999","journal-title":"Biochem J"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0270","first-page":"5248","article-title":"A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jmedgenet-2011-100714","article-title":"Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification","volume":"49","author":"Parsons","year":"2012","journal-title":"J Med Genet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10689-007-9124-1","article-title":"Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary nonpolyposis colorectal cancer","volume":"6","author":"Loughrey","year":"2007","journal-title":"Fam Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0285","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/jmg.2004.020651","article-title":"BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing","volume":"41","author":"Domingo","year":"2004","journal-title":"J Med Genet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0290","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1349-7006.2010.01712.x","article-title":"Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes","volume":"102","author":"Kaneda","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0300","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/PAP.0b013e31819923b3","article-title":"Pathologic features and biologic importance of colorectal serrated polyps","volume":"16","author":"Vakiani","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/path.2160","article-title":"Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis","volume":"212","author":"Minoo","year":"2007","journal-title":"J Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0310","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/ng1834","article-title":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","volume":"38","author":"Weisenberger","year":"2006","journal-title":"Nat Genet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0315","doi-asserted-by":"crossref","first-page":"698","DOI":"10.5858\/2010-0523-RA.1","article-title":"Four molecular subtypes of colorectal cancer and their precursor lesions","volume":"135","author":"Kang","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0320","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1158\/0008-5472.CAN-08-1171","article-title":"Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases","volume":"68","author":"Barault","year":"2008","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0325","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1827.2007.02197.x","article-title":"Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS\/BRAF mutation","volume":"58","author":"Lee","year":"2008","journal-title":"Pathol Int"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0330","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","article-title":"Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803","volume":"18","author":"Ogino","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0335","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/bjc.2011.19","article-title":"BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer","volume":"104","author":"Yokota","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0340","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/annonc\/mdq258","article-title":"The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients","volume":"21","author":"Farina-Sarasqueta","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0345","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/PAS.0b013e31824430d7","article-title":"BRAF-mutated, microsatellite- stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features","volume":"36","author":"Pai","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0350","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0355","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.6004\/jnccn.2009.0056","article-title":"NCCN Clinical Practice Guidelines in Oncology: colon cancer","volume":"7","author":"Engstrom","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0365","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jocn.2012.01.028","article-title":"Paediatric brain tumours treated at a single, tertiary paediatric neurosurgical referral centre from 1999 to 2010 in Australia","volume":"19","author":"Ramanan","year":"2012","journal-title":"J Clin Neurosci"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0370","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00401-010-0693-y","article-title":"RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort","volume":"120","author":"Lawson","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0375","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/onc.2009.73","article-title":"Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma","volume":"28","author":"Jones","year":"2009","journal-title":"Oncogene"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0380","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00401-009-0550-z","article-title":"Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma","volume":"118","author":"Korshunov","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0385","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0390","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0395","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00401-011-0817-z","article-title":"Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma","volume":"121","author":"Cin","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0400","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ijc.25893","article-title":"Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma","volume":"129","author":"Eisenhardt","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0405","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0410","doi-asserted-by":"crossref","first-page":"e17948","DOI":"10.1371\/journal.pone.0017948","article-title":"BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications","volume":"6","author":"Dias-Santagata","year":"2011","journal-title":"PloS One"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0415","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis ofBRAFV600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0420","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00018-011-0898-9","article-title":"MAPK pathway activation in pilocytic astrocytoma","volume":"69","author":"Jones","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0425","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2990.2011.01193.x","article-title":"BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults","volume":"37","author":"Hasselblatt","year":"2011","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0430","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5858\/2010-0649-RAIR.1","article-title":"Molecular diagnostics of gliomas","volume":"135","author":"Nikiforova","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0435","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-009-0634-9","article-title":"Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas","volume":"119","author":"Horbinski","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0440","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-09-3064","article-title":"Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response","volume":"16","author":"Pratilas","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0445","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1158\/1078-0432.CCR-11-1456","article-title":"targeted therapy for BRAFV600E malignant astrocytoma","volume":"17","author":"Nicolaides","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0450","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jcp.21978","article-title":"MAPK pathway activation and the origins of pediatric low-grade astrocytomas","volume":"222","author":"Tatevossian","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0455","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0460","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0465","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jss.2005.10.022","article-title":"Uncommon V599E BRAF mutations in Japanese patients with lung cancer","volume":"133","author":"Sasaki","year":"2006","journal-title":"J Surg Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0470","first-page":"7001","article-title":"Missense mutations of the BRAF gene in human lung adenocarcinoma","volume":"62","author":"Naoki","year":"2002","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0475","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0480","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/0008-5472.CAN-06-4592","article-title":"Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models","volume":"67","author":"Ji","year":"2007","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0485","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1101\/gad.1516407","article-title":"A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors","volume":"21","author":"Dankort","year":"2007","journal-title":"Genes Dev"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0490","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0495","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0500","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1038\/cddis.2011.136","article-title":"BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy","volume":"3","author":"Colombino","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0505","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0510","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.biopha.2010.06.009","article-title":"KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients","volume":"65","author":"Xu","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0515","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00428-004-1046-9","article-title":"Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability","volume":"445","author":"Saetta","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0520","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0525","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3324\/haematol.2011.054874","article-title":"Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders","volume":"97","author":"Blombery","year":"2012","journal-title":"Haematologica"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0530","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2011-08-368209","article-title":"The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms","volume":"119","author":"Arcaini","year":"2012","journal-title":"Blood"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0535","first-page":"1639","article-title":"Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma","volume":"25","author":"Kim","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0540","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00414-011-0549-6","article-title":"Factors affecting the detection and quantification of mitochondrial point heteroplasmy using Sanger sequencing and SNaPshot minisequencing","volume":"125","author":"Naue","year":"2011","journal-title":"Int J Legal Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0545","doi-asserted-by":"crossref","first-page":"e49602","DOI":"10.1371\/journal.pone.0049602","article-title":"Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism","volume":"7","author":"Archer","year":"2012","journal-title":"PLoS One"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0550","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0555","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/PAS.0b013e318246b527","article-title":"Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma","volume":"36","author":"Koperek","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0560","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases","volume":"123","author":"Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0565","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/PAI.0b013e31825d7402","article-title":"Expression of BRAF V600E mutant protein in epithelial ovarian tumors","volume":"21","author":"Preusser","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0570","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0575","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0580","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0585","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0590","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0595","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11640870-000000000-00000","article-title":"Vemurafenib: Targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies","volume":"72","author":"Sharma","year":"2012","journal-title":"Drugs"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0600","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0605","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0610","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1017\/S146239941100202X","article-title":"Towards new therapeutic approaches for malignant melanoma","volume":"13","author":"Pacheco","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0615","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1535-7163.MCT-11-0645","article-title":"CEP-32496: A novel orally active BRAFV600E inhibitor with selective cellular and in vivo antitumor activity","volume":"11","author":"James","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0620","doi-asserted-by":"crossref","first-page":"336","DOI":"10.18632\/oncotarget.262","article-title":"Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers","volume":"2","author":"Corcoran","year":"2011","journal-title":"Oncotarget"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0625","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0630","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0635","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0640","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci Signal"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0645","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0650","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","article-title":"Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY- 142886) in Braf-mutant human cutaneous melanoma cells","volume":"70","author":"Gopal","year":"2010","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0655","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/13543784.2010.527945","article-title":"PLX4032: does it keep its promise for metastatic melanoma treatment?","volume":"19","author":"Livingstone","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0660","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous Manifestations of Dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0665","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23","author":"Robert","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0670","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0675","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamouscell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0680","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0685","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0690","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/DAD.0b013e3182604873","article-title":"Squamoproliferative lesions arising in the setting of BRAF inhibition","volume":"34","author":"Harvey","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0695","doi-asserted-by":"crossref","first-page":"423239","DOI":"10.1155\/2011\/423239","article-title":"BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance","volume":"2011","author":"Sullivan","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0700","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2010-0317","article-title":"Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer","volume":"16","author":"Nucera","year":"2011","journal-title":"Oncologist"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0705","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/en.2011-1519","article-title":"Late intervention with anti- BRAFV600E therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer","volume":"153","author":"Nehs","year":"2012","journal-title":"Endocrinology"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0710","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1158\/1535-7163.MCT-12-0290","article-title":"Molecular profiling of patients with colorectal cancer and matched targeted therapy in Phase I clinical trials","volume":"11","author":"Dienstmann","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0715","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e328360b61d_bib0720","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516315392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516315392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:10:07Z","timestamp":1715213407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302516315392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":144,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0031302516315392"],"URL":"https:\/\/doi.org\/10.1097\/pat.0b013e328360b61d","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}